Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

Proteolysis targeting chimeras (PROTACs) are heterobifunctional small molecules that utilize the ubiquitin proteasome system (UPS) to degrade proteins of interest (POI). PROTACs are potentially superior to conventional small molecule inhibitors (SMIs) because of their unique mechanism of action (MOA...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Yonghan, Khan, Sajid, Huo, Zhiguang, Lv, Dongwen, Zhang, Xuan, Liu, Xingui, Yuan, Yaxia, Hromas, Robert, Xu, Mingjiang, Zheng, Guangrong, Zhou, Daohong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384229/
https://www.ncbi.nlm.nih.gov/pubmed/32718354
http://dx.doi.org/10.1186/s13045-020-00924-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384229/
https://www.ncbi.nlm.nih.gov/pubmed/32718354
http://dx.doi.org/10.1186/s13045-020-00924-z

Ejemplares similares